| Date | Title | Description |
| 04.08.2017 | Learning from failure: What Theranos, Interleukin Genetics, & Courtagen can teach us about IVDs | Developing and commercializing an in vitro diagnostic (IVD) is a complex enterprise involving numerous tasks accomplished by a variety of specialized and knowledgeable individuals. Generally, the process can be broken down into product conc... |
| 20.05.2013 | Interleukin Genetics Announces $12 Million Private Placement | WALTHAM, Mass. – May 20, 2013 – Interleukin Genetics, Inc. (OTCQB: ILIU) announced today that it has raised $12.0 million in gross proceeds through a private placement of its securities to accredited investors. Interleukin sold an aggregate... |
| 15.11.2010 | Clinical trials roundup: Medtronic study to boost CRT-D industry? | Cardiac resynchronization-therapy defibrillators reduced the mortality rate by 29 percent in patients with mild symptoms of heart failure, according to a study released by Medtronic Inc. (NYSE:MDT) at the annual meeting of the American Hear... |
| 30.04.2010 | Interleukin adds VC vet to board | Interleukin Genetics Inc. (NYSE:ILI) named a venture capital veteran, William Mills III, to its board of directors.
Mills will replace the Waltham, Mass.-based company’s founder, president and chief scientific officer Ken Kornman if shareho... |
| 05.03.2010 | Interleukin raises $5 million | Interleukin Genetics Inc. (NYSE:ILI) drummed up about $5.3 million in commitments from institutional investors in a registered direct offering.
The Waltham, Mass.-based genetic test maker said it expects to pull in $4.9 million after deduct... |
| 02.03.2010 | Interleukin named in patent suit by Australian genetic testing firm | Interleukin Genetics Inc. (NYSE:ILI) and seven other firms were named in a patent infringement lawsuit filed by an Australian genetic testing company.
Genetic Technologies Ltd. of Victoria, Australia, asserts that Interleukin is one of eigh... |
| - | Learning from failure: What Theranos, Interleukin Genetics, & Courtagen can teach us about IVDs | In the aftermath of the Theranos downfall, dozens of pundits have performed virtual autopsies of where CEO Elizabeth Holmes went wrong, generally highlighting a lack of full disclosure about the technology its labs were using. In the beginn... |
